Yesim Gökmen-Polar
Department of Medicine
Indiana University School of Medicine
Walther Hall
980 W Walnut Street
USA
Name/email consistency: high
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Gökmen-Polar, Y., Liu, Y., Toroni, R.A., Sanders, K.L., Mehta, R., Badve, S., Rommel, C., Sledge, G.W. Breast Cancer Res. Treat. (2012)
- Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Gökmen-Polar, Y., Mehta, R., Tuzmen, S., Mousses, S., Thorat, M.A., Sanders, K.L., Turbin, D., Leung, S., Huntsman, D.G., Sledge, G.W., Badve, S. Breast Cancer Res. Treat. (2010)
- beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Gökmen-Polar, Y., Escuin, D., Walls, C.D., Soule, S.E., Wang, Y., Sanders, K.L., Lavallee, T.M., Wang, M., Guenther, B.D., Giannakakou, P., Sledge, G.W. Cancer Res. (2005)